Caldwell & Orkin’s Amedisys AMED Stock Holding History

Caldwell & Orkin’s Portfolio AMED Stock Details AMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-24,000	Closed	-$911K	–	78
2015 Q3	$911K	Buy	+24,000	New	+$1.01M	0.58%	54

Other funds holding AMED

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NTC

North Tide Capital Boston, Massachusetts $469M AUM 6.57% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Caldwell & Orkin's AMED Position: Q4 2015 in Review

Caldwell & Orkin sold out of Amedisys (AMED) in Q4 2015, closing a stake of 24,000 shares — an estimated $911K sold.

Caldwell & Orkin first reported a position in AMED in Q3 2015 and held it in 1 quarter. The position peaked at $911K in Q3 2015. 165 funds tracked by Wall St. Rank hold AMED as of Q4 2015.

Caldwell & Orkin reported no remaining Amedisys position as of Q4 2015 after selling out during the quarter.
Caldwell & Orkin sold 24,000 Amedisys shares in Q4 2015, an estimated $911K.
Caldwell & Orkin first reported a position in Amedisys in Q3 2015 and held it in 1 quarter.
Caldwell & Orkin's Amedisys position peaked at $911K in Q3 2015.
165 funds tracked by Wall St. Rank held Amedisys as of Q4 2015.

Based on Caldwell & Orkin's 13F filing for Q4 2015, filed 10 Feb 2016.